Skip to content
HowShorted

Alaunos Therapeutics, Inc. short interest in 2020

In 2020, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 30.23% of shares outstanding on 15 Jan 2020 to 15.64% on 31 Dec 2020, a change of -14.59 percentage points. The year's high was 30.23% on 15 Jan 2020 and its low 11.68% on 15 Jun 2020, averaging 16.12% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.74 days on 31 Jan 2020. Full history: Alaunos Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Alaunos Therapeutics, Inc. in 2020

2020 in figures

Start of year
30.23% (15 Jan 2020)
End of year
15.64% (31 Dec 2020)
Change
-14.59 pp
High
30.23% (15 Jan 2020)
Low
11.68% (15 Jun 2020)
Average
16.12%
Highest days to cover
36.74 (31 Jan 2020)
SEC filings marked
9

Every report in 2020

Alaunos Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202030.23%32.05
31 Jan 202029.97%36.74
14 Feb 202016.76%10.29results (8-K)
28 Feb 202016.15%18.00
13 Mar 202015.90%13.3510-K filed, results (8-K)
31 Mar 202015.10%14.24
15 Apr 202014.48%25.64
30 Apr 202013.30%23.05
15 May 202011.99%17.6010-Q filed, results (8-K)
29 May 202011.93%13.63
15 Jun 202011.68%13.50
30 Jun 202014.99%10.64
15 Jul 202015.14%22.49
31 Jul 202015.00%26.05
14 Aug 202014.91%15.2010-Q filed, results (8-K)
31 Aug 202014.64%27.80
15 Sep 202014.66%22.53
30 Sep 202015.77%23.11
15 Oct 202016.16%34.83
30 Oct 202015.63%23.45
13 Nov 202015.60%24.0710-Q filed, results (8-K)
30 Nov 202015.56%26.43
15 Dec 202015.59%19.41
31 Dec 202015.64%12.78

See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.